Improving Free Cash Flow BurnFree cash flow burn has improved versus 2024, indicating management has taken actions to reduce cash outflows. A sustained reduction in cash burn lengthens runway, lowers near-term refinancing pressure, and provides a structurally stronger footing for executing a turnaround over the next several months.

Quality Of Reported LossesFree cash flow tracking net income at roughly 1x suggests losses are largely cash-based rather than driven by distortive non-cash items. That improves the reliability of cash forecasts and makes financing needs more predictable, a durable advantage for planning operational recovery or restructuring.

Smaller Net Losses Vs 2023Net losses have narrowed relative to an unusually large 2023 loss, implying progress on cost control or one-time issue remediation. If sustained, this reduction in loss magnitude supports improving leverage on any future revenue gains and reduces cumulative deficit growth over a multi-quarter horizon.

Bears Say

Tiny, Shrinking Revenue BaseRevenue is extremely small and declined ~22% YoY, which undermines the company’s ability to achieve scale or cover fixed costs. A contracting top line is a structural headwind: without credible, durable revenue growth the business cannot sustainably absorb operating expenses or fund reinvestment.

Negative Gross Profit And Persistent LossesNegative gross profit indicates the core product economics do not cover direct costs, a fundamental business-model flaw. Persistent operating losses mean margins are structurally unsustainable unless product pricing, cost structure, or the revenue mix are materially changed over the medium term.

Deeply Negative Equity / Stressed Balance SheetEquity is deeply negative (~-10.6M) against a tiny asset base, reflecting accumulated deficits and a fragile capital structure. This materially limits financial flexibility, increases reliance on external funding or restructuring, and is a long-running solvency risk absent decisive recapitalization.

Biosenta Inc News

Biosenta to Test Antimicrobial Nanoparticles in Alberta Residential Project

The latest update is out from Biosenta Inc ( ($TSE:ZRO) ). Biosenta Inc. has entered into a Field...

3M ago

Biosenta Inc. Strengthens Advisory Board with Industry Veteran

Biosenta Inc ( ($TSE:ZRO) ) has issued an announcement. Biosenta Inc. has announced the addition of Gary LeRoux,...

6M ago

Biosenta’s Tri-Filler™ Achieves 100% Pathogen Elimination in Studies

Biosenta Inc ( ($TSE:ZRO) ) has shared an update. Biosenta Inc. announced that its Tri-Filler™ nanoparticles achieved 100%...

9M ago

Biosenta Inc. Innovates for Eco-Friendly Future

Biosenta Inc (TSE:ZRO) has released an update. Biosenta Inc. has announced notable progress in their bench scale production,...

2y ago

ZRO

Biosenta Inc. Secures Key Licensing Deal

Biosenta Inc (TSE:ZRO) has released an update. Biosenta Inc. has reached a significant milestone by sealing an exclusive...

2y ago

ZRO

Biosenta Inc. Secures $600K in Private Funding

Biosenta Inc (TSE:ZRO) has released an update. Biosenta Inc., a Canadian company specializing in safe and environmentally friendly...

2y ago

ZRO

Biosenta Inc. Launches $600K Private Placement

Biosenta Inc (TSE:ZRO) has released an update. Biosenta Inc. has launched a non-brokered private placement offering aimed at...

2y ago

ZRO

Biosenta Triumphs with Tri-Filler™ Production Milestone

Biosenta Inc (TSE:ZRO) has released an update. Biosenta Inc. has successfully initiated its bench scale production plant, significantly...

2y ago

ZRO

ZRO FAQ

What was Biosenta Inc’s price range in the past 12 months?

Biosenta Inc lowest stock price was C$0.07 and its highest was C$0.17 in the past 12 months.

What is Biosenta Inc’s market cap?

Biosenta Inc’s market cap is C$2.78M.

When is Biosenta Inc’s upcoming earnings report date?

Biosenta Inc’s upcoming earnings report date is Jun 03, 2026 which is in 78 days.

How were Biosenta Inc’s earnings last quarter?

Currently, no data Available

Is Biosenta Inc overvalued?

According to Wall Street analysts Biosenta Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Biosenta Inc pay dividends?

Biosenta Inc does not currently pay dividends.

What is Biosenta Inc’s EPS estimate?

Biosenta Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Biosenta Inc have?

Biosenta Inc has 34,768,887 shares outstanding.

What happened to Biosenta Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Biosenta Inc?

Currently, no hedge funds are holding shares in TSE:ZRO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Biosenta Inc

Biosenta Inc. develops, manufactures, and sells anti-microbial chemical compounds for household and industrial applications in Canada. It is involved in developing true, an anti-microbial, dual-action disinfectant that kills viruses, bacteria, mold, and germs on contact. The company also intends to manufacture and distribute Tri-Filler, an anti-microbial filler to perform filling and bulking functions. Biosenta Inc. was founded in 1986 and is based in Toronto, Canada.